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[571 ABSTRACT 
HSA crystals are provided in the form of tetragonal 
plates having the space groups P4212, the crystals being 
grown to sizes in excess of 0.5 man in two dimensions 
and a thickness of 0.1 mm. Growth of the crystals is 
carried out by a hanging drop method wherein a precip- 
itant solution containing PEG and a phosphate buffer is 
mixed with an HSA solution, and a droplet of mixed 
solution is suspended over a well of precipitant solution. 
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HUMAN SERUM ALBUMIN CRYSTALS AND 
METHOD OF PREPARATION 
ORIGIN OF THE INVENTION 
The invention described herein was made by an em- 
ployee of the United States Government and may be 
manufactured and used by or for the government of the 
United states of America for governmental purposes 
without the payment of any royalties thereon as there- 
for. 
TECHNICAL FIELD 
This invention relates to protein crystal growth and 
more particularly to the preparation of crystals of 
human serum albumin in a form and size suitable for 
x-ray studies of crystal structure. 
BACKGROUND OF 'THE INVENTION 
Serum' albumin, a protein of multiple functions and 
manifold applications, is one of the most extensively 
studied proteins in biochemistry. Over 25,000 literature 
citations involving the biochemistry and/or applica- 
tions of serum albumins have been published since 1969. 
The mammalian serum albumins proteins are known to 
be the product of three tandem gene duplications, and 
possess high helical content (60%) and high cystiene 
content (17 disulphides) with approximate molecular 
weights in the range of 65,000 daltons. Complete amino 
acid sequences are known for bovine, rat, and human 
serum albumins. Although the principal function of 
serum albumin remains unknown, it contributes to many 
transport and regulatory processes. Many studies have 
focused on the multifunctional binding properties of this 
interesting protein which range from various metals, 
e.g. Ca and Cu, to fatty acids, hormones, and a wide 
spectrum of therapeutic drugs. The majority of these 
binding studies have involved the human serum albumin 
(HSA) and many have shown that the distribution, free 
concentration, and metabolism of various pharmaceuti- 
cals can be significantly altered as a function of the 
magnitude of binding to HSA. 
A detailed knowledge of the three-dimensional struc- 
ture of serum albumin is imperative in order to fully 
understand the binding modes as well as many of the 
physical properties of this multifaceted protein. In addi- 
tion, since many newly developed pharmaceuticals are 
rendered less effective by HSA, it is apparent that the 
crystal structure of a serum albumin, particularly the 
A5 
human form, will find very broad and significant appli- 
cation in the area of rational drug design. Consequently, 
the serum albumins have been the subject of ongoing 
crystallographic investigation which includes the docu- 
5 mentation of several crystal forms (Table 1). Because of 
difficulties with crystal size, quality, and/or reproduc- 
ibility, the three-dimensional structure of a serum albu- 
min remains unknown. 
This invention is concerned with the methodology 
10 required to produce a new crystal form of HSA which 
can be grown reproducibly as large, relatively high 
quality crystals suitable for x-ray structure determina- 
tion. Once the three dimensional structure has been 
determined it will become possible to learn the molecu- 
15 lar details involved in the binding of the albumin with a 
large number of pharmaceutical compounds. This may 
be done by soaking crystals in an appropriate stabilizing 
solution which contains the drug molcules of interest. If 
the binding sites are available in this crystal form, a 
20 crystalline array containing the serum albumin 'protein 
and the drug molecule will be produced. Details of the 
molecular interaction between the drug and protein can 
then be determined by established procedures in x-ray 
crystallography. 
Due to the multiple binding capabilities of HSA, 
knowledge of its three dimensional structure combined 
with suitable crystals, may also provide assistance in 
determining the structures of various small molecules 
and perhaps small proteins which have proven difficult 
Crystals of human serum albumin have been known 
for some time. As early as 1952, large crystals of HSA 
had been grown. Detailed x-ray examination of these 
and other reported crystal forms, including crystals of 
35 Horse serum albumin were published by McClure and 
Craven in 1974 (1) See Table 1, below. Crystals of HSA 
have also been grown by Rao and co-workers (2). Table 
1 summarizes the crystallographic data published to 
date on several human serum albumin crystal forms. 
25 
30 to crystallize. 
40 
45 
According to Peters in a recent review (1985) on serum 
albumins (3): 
Although readily crystallized, albumin has relin- 
quished few of its secrets through x-ray crystallography 
to date. ~ . . Structural information from these crystals is 
awaited eagerly, but obtaining it appears to be fraught 
with obstacles. Low described monoclinic crystals as 
soft waxy, and crystals studied by Rao, et ai. (1976) 
have tended to dissolve under study. 
TABLE 1 
CRYSTAL DATA ON THE POLYMORPHS OF HUMAN SERUM ALBUMIN 
Crystal System 
Monoclinic Orthorhombic Orthorhombic Tetragonal Tetragonal 
Space Group 
Unit Cell 
Dimensions 
Unit Cell 
Volume A3 
Molecules/ 
Asymmetric Unit 
Diffraction 
Limits A 
Matthews 
Solvent Fraction 
- Coefficient* 
a = 126.5(3) 
b = 39.2(1) 
c = 135.2(3) 
B = 93.3(1) 
668,900 1,570,000 
1 2 
a = 155(1) 
b = 83(1) 
c = 122(1) 
2.7 3.7 
2.52 2.95 
52% 
P21212 
a = 137.3(1) 
b = 275(3) 
c = 58.02(2) 
2,125,000 
3 
3.0 
2.66 
59% 
P41212 P4212 
Or 
P43212 
a = 84.q5) a = 187(1) 
c = 276(3) c = 81(1) 
1,947,000 2,832,000 
1 2 
3.8 2.9 
3.66 2.66 
54% 67% 54% 
3 
4,833,23 3 
4 
TABLE I-continued 
CRYSTAL DATA ON THE POLYMORPHS OF HUMAN SERUM ALBUMIN 
Crystal System 
Monoclinic Orthorhombic Orthorhombic Tetragonal Tetragonal 
References (1) (1) (2) (1) This work 
‘Based on HSA MW 66458 
References 
1. R. J. McClure and E. M. Craven, J. Mol. Biol. (1974) 83, 551-555 
2. Rao, S. N. et al. (1976) J. Biol. Chem., 251, 3191-3193 
3. T. Peters, Advances in Protein Chemistry, Vol. 37, pg 161-243, (1985) 
FIG. 4 is a schematic drawing showing a proposed 
packing arrangement of HSA molecules in crystals 
prepared in accordance with the invention. 
Crystals of the monoclinic form reported by McClure 
and Craven appear to be the highest quality; unfortu- 
DETAILED DESCRIPTION OF THE 
INVENTION 
nately, the crystals are small andhifficult to reproduce. 15 
It is difficult to adequately compare the crystal quality 
of the remaining tetragonal crystal form with the tetrag- 
onal crystal f o k  reported here, since the diffraction 
resolution reported for that crystal form was obtained 
with a conventional sealed tube source. 
It is therefore an object of this invention to provide 
HSA in the form of crystals amenable to use in x-ray 
diffraction studies. 
Another object is to provide HSA crystals having a 
size of at least 0.5 mm in two dimensions. 
Yet another object is to provide HSA crystals in a 
form suitable for drug binding studies. 
Still another object is to provide a method of prepar- 
ing such crystals. 
HSA crystals embodying the invention may be 
grown from a precipitant solution of polyethylene gly- 
20 col (PEG), and a buffer, with concentration of reagents 
and pH being carefully controlled within prescribed 
limits. Any of the three basic techniques generally used 
for growth of protein crystals, that is, “hanging drop” 
or vapor diffusion, dialysis and batch methods may be 
In the hanging drop method a small drop of protein 
solution is placed on a cover slip, or glass plate, which 
is inverted over a well of solution and sealed. The solu- 
tion in the well contains a precipitating agent, which is 
30 also present in a lesser amount in the protein droplet. 
The function of the precipitating agent is twofold. First, 
25 employed, but the hanging-drop method is preferred. 
SUMMARY OF THE INVENTION 
In accordance with the present invention human the solution in the well is initially at a lower vapor 
serum albumin crystals are provided in the form of pressure than the protein droplet so that evaporation 
tetragonal plates having the space groups P4212. These progresses at a rate fixed by the difference in the vapor 
crystals may be readily grown to a size well in excess of 35 messures and the distance by which the vapor (usually 
0.5 mm in two dimensions and a thickness of 0.1 mm, 
this size enabling effective x-ray diffraction studies from 
which molecular configuration may be deduced. The 
crystals grow - from solutions of polyethylene glycol, 
which will provide for the added advantage of solubiliz- 
ing various pharmaceutical and biological compounds 
for binding studies. Human serum albumin is known to 
undergo substantial conformational change with 
changes in pH. This crystal form is the only one to grow 
under conditions of physiological pH, and therefore 
will provide the most relevant information with regard 
to drug binding studies. Crystallization conditions are 
reproducible, and the crystals diffract to resolutions 
adequate to determine the nature of the binding modes 
of various biological and pharmaceutical compounds. 
Crystals prepared in accordance with the invention may 
also prove useful in conduct of genetic engineering 
studies. 
Crystal growth may be readily carried out by a 
“hanging-drop” method using a polyethylene glycol 
solution and a monobasic potassium phosphate buffer- 
ing agent, with solution pH being adjusted prior to 
initiation of crystal growth. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Details of the invention will become apparent from 
FIG. 1 is a photograph showing a crystal of HSA 
FIG. 2 is an x-ray precession photograph of such a 
FIG. 3 is an x-ray oscillation photograph of an HSA 
the accompanying drawings wherein: 
embodying the invention; 
crystal; and 
crystal; 
Later) must diffuse. Secondly, the precipifating agent 
lowers the solubility of the protein in solution by com- 
peting with the protein for available solvent, and thus as 
evaporation from the protein droplet occurs the solu- 
40 tion becomes supersaturated in protein. Under the ap- 
propriate conditions including pH, protein concentra- 
tion and temperature, crystallization of the protein or 
macromolecule then occurs. 
The precipitant solution for use in the hanging drop 
45 method is made up to contain PEG at a molecular 
weight of 180 to 800, and preferably about 400 and a 
concentration of 35 to 45 volume percent, with best 
results being obtained at 40 volume percent, and a 
buffer in an amount sufficient to provide the required 
50 pH. Monobasic potassium phosphate at a concentration 
of 0.05 to 0.1M may be used for this purpose. Other 
buffers such as sodium acetate, sodium citrate and Tris 
(hydroxymethyl) aminomethane-maleate may also be 
used. 
obtained after mixing of PEG and buffer is critical to 
effective and reproducible growth of HSA crystals. A 
solution pH of 4.6 to 7.2 may be used, with best results 
being obtained at a pH of about 7.2. In a preferred pro- 
60 cedure the precipitant solution pH is adjusted after 
mixing to compensate for variations in pH which may 
arise from variation in molecular weight and residue 
content of PEG. Adjustment of pH is readily carried 
out by addition of small amounts of a solution of a base 
65 such as potassium hydroxide or an acid such as hydro- 
chloric acid until the desired value is obtained. 
HSA may be provided in the form of an aqueous 
solution at a concentration of 90 to 200 mg per ml, with 
55 I have found that the pH of the precipitant solution. 
5 
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best results being obtained at 200 mg per ml. Use of 
HSA that is essentially free of fatty acids is preferred. In 
carrying out the hanging drop method a droplet of this 
solution, typically comprising 10 microliters, and a 
droplet containing an equal volume of precipitant soh- 5 
tion would be placed on a cover slip and allowed to mix. 
A larger amount such as 1 ml of precipitant solution, 
without HSA, would be disposed in the well of the 
apparatus. 
ing anode source. An x-ray precession photograph thus 
obtained is shown in FIG. 2 of the drawings. 
EXAMPLE 2 
HSA crystals were grown by the procedure of Exam- 
ple 1, except that the concentration of KH2P04 was 
0 . M  in the precipitant solution, and solution pH was 
adjusted to 6.2 prior to miXing with HSA. OSCillatiOII 
photographs were taken on an Enraf-NoniuS Amdt- . Crystals grow from these periods in 3 to 10 days to 10 Wanacott camera at the Brookhaven Synchrotron 
Light Source operating at 2.5 GeV with a beam current 
between 120 and 45 ma. An oscillation photograph so 
Obtained is shown in 
dimensions of 0.05 xO.5 x 0.5 mm to 2.Ox 2.Ox 0.3 mm. 
ne variations in the times for crystal growth are a 
function of protein concentration and pH. At concen- Of the 
trations of 200 mg per X-ray procession photographs indicate 4 mm symme- 
growth times are typically 5 days. For x-ray diffraction 15 try for the hko zone and - symmetry for the hhl, hO1 and pH values from 6.8 to 7.2 
experiments the crystals are transferred from the hang- 
ing drop to a 
spending reservoir solution, i.e. 40% PEG 4oo in o.05 
phosphate buffera The crystals are stable in these 
solution at 
stabilizing solution may be adjusted to enhance 
binding of molecules for diffraction studies, in most 
cases without destroying the crystals. 
exclusion membrane which retains the protein but al- 
agents) to diffuse in and out. Essentially identical condi- 
tions to those determined for the hanging drop method 
tals. In dialysis, rather than concentrating the protein 
and Okl =Ones* The and Ok0 ‘Ones show system- 
matic absences for h or k=2n+ 1. There are no system- 
matic absences along the 001 direction. The space 
group is therefore concluded to be P4212. Consistent 
for long periods of time. The pH of this 20 with the presence of an isotropic axis, the crystals do 
not extinguish polarized light when viewed down the 
four fold axis. Unit cell constants as measured from 
precession photographs were found to be a=b= 187(1) 
and c=81(1) A. A crystal density of 1.138 g/cm3 was 
for indicates two protomers per asymmetric 
2.6 A3/dalton and implies a solvent content of 54 per- 
cent. 
tion of the 
to 20 microliter droplet of the 
The dialysis method utilizes a size 25 determined using aqueous ~ i ~ ~ l l  gradients. This value 
lows (buffers and precipitating which corresponds to a Matthews coefficient of 
( Or vice versa) can then be to grow protein crys- 30 FIG. 4 of the drawing illustrates a proposed orienta- 
molecules in the asymmetric unit of the 
and the precipitating agent by evaporation, the precipi- 
tating agent is allowed to slowly diffuse through the 
p4212 form. In this packing arrangement the shaded and 
unshaded molecules are related by a pseudo twoafold 
membrane and reduce the solubility of the protein keep- rotation forming a subcell with =bf= 132 A !s 
ing the protein concentration fixed. 35 required and possessing a molecular length of 100 A. 
The batch methods generally involve the Slow addi- Packing considerations in this caseo appear to limit the 
tion of a Precipitating agent to an aqueous solution of molecular length t9 values of 130 A or less and values 
protein until the solution just becomes turbid, at this near 100 to 110 A Seem appropriate, although 
point the container is sealed and left undisturbed for a solution and electron !iffraction studies estimate a mo- 
predetermined time. 40 lecular length of 140 A. The subcell shown in FIG. 4 
In practice, Once the Precipitating would possess P422 pseudo-symmetry and contain one 
agent(s) buffer@) and other experimental variables have molecule per asymmetric unit. 
been determined for any given growth method, any of While a preferred embodiment of the invention has 
these methods or others unmentioned could be used to been described using specific terms, such description is 
grow crystals of a given protein. Thus these features as 45 for illustrative purposes only, and it is to be understood 
de%xhd above for growing HSA by the hang% drop that changes and variations may be made without de- 
method may also be applied to growing HSA by batch parting from the spirit or scope of the following claims. 
or dialysis methods. I claim: 
The invention is further illustrated by the following 1. An ]HSA crystal in the form of tetragonal plates 
specific examples. 50 having the space group P4212 and the following unit 
cell constants: a=b= 187(1)A, c=81(1). 
2. A crystal as defined in claim 1 having a size of at 
least 0.5 n m  in two dimensions and a thickness of at 
least 0.05 mm. 
3. A crystal as defined in claim 2 having a size of 
0 . 5 ~ 0 . 5 ~ 0 . 0 5  mm to 2.0~2.0X0.3 mm. 
4. A crystal as defined in claim 1 having a crystal 
density of 1.138 g/cm3. 
5. The method of growing crystals of HSA which 
providing an aqueous solution of HSA at a concentra- 
tion of 90 to 200 mg per ml; 
providing an aqueous precipitant solution Comprising 
PEG at a concentration of 35 to 45 volume percent 
and a buffer at a concentration such as to povide a 
pH of 4.6 to 7.2; 
mixing a droplet of said HSA solution with a droplet 
of said precipitant solution; 
EXAMPLE 1 
Crystals of HSA were grown from PEG using hang- 
ing drop procedures and apparatus. 5 p1 portions of 35 
to 40 percent PEG (molecular weight 400) in 0.05M 55 
KH2P04, pH 4.6, were added to equal portions of 120 
to 180 mg/ml HSA, placed on glass cover slips inverted 
and sealed over wells containing 1 ml40 percent PEG 
in 0.1 M m 2 P o 4 .  Crystals appeared in 24 to 48 hours 
in the form of tetragonal plates and reached a size of 0.6 60 comprises: 
by 0.3 mm by 0.1 mm thick in 3 to 4 days. A photograph 
of one of the resulting crystals is shown in FIG. 1 of the 
drawings. 
Crystals prepared as described above were trans- 
ferred to a stabilizing solution of 35 to 40 percent PEG 65 
400 in 0.1 M KH2PO4 and mounted in glass capillaries. 
X-ray precession photographs of resulting crystals were 
taken on a Supper camera with a Rigaku RU200 rotat- 
7 
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suspending the resulting mixed droplet over a well of 
precipitant solution in a sealed container, the vapor 
pressure of the solution in said well being lower 
than in the resulting solution in the mixed droplet; 
and 
allowing the suspended mixed droplet to stand for a 
prolonged period until an HSA crystal therein 
grows to a predetermined size. 
6. The method of claim 5 wherein said buffer is mono- 
7. The method of claim 6 wherein the concentration 
8. The method of claim 7 wherein said precipitant 15 
10 
basic potassium phosphate. 
of said buffer is 0.05 to 0.1 M. 
solution is prepared by mixing a PEG solution with a 
buffer and adjusting the pH of the resulting mixed solu- 
tion. 
9. TRe method of claim 8 wherein said mixed droplet 20 
is allowed to stand for a period of 3 to 7 days. 
18. The method of claim 9 wherein said mixed droplet 
is allowed to stand until said crystal grows to a size of 
0.5><0.5x0.05 mm to 2.0x2.0x0.3 mm. 
11. The method of claim 10 wherein the molecular 
weight of said PEG is 180 to 800. 
12. The method of claim 11 wherein the average 
molecular weight of said PEG is about 400. 
25 
30 
13. The method of claim 12 wherein the concentra- 
tion of HSA in said aqueous solution is about 200 mg 
per mi. 
14. The method of claim 7 wherein the pH of said 
precipitant solution is adjusted to a value of 4.8 to 7.2. 
15. The method of claim 14 wherein said pH is ad- 
justed to a value of 7.2. 
. 16. The method of growing crystals of HSA which 
comprises: 
providing an aqueous solution of HSA at a concentra- 
tion of 90 to 200 mg per ml; 
providing an aqueous precipitant solution comprising 
PEG at a concentration of 35 to 40 volume percent 
and a buffer at a concentration such as to provide a 
pH of 4.6 to 7.2; 
combining said HSA solution with said precipitant 
solution and allowing the resulting solution to 
stand for a predetermined period until an HSA 
crystal therein grows to a predetermined size. 
17. The method of claim 16 wherein said MSA solu- 
tion is disposed within a semipermeable size exclusion 
membrane and said precipitant solution is combined 
with the HSA solution by diffusion through said mem- 
brane. 
18. The method of claim 16 wherein said precipitant 
solution is combined with said MSA solution by slow 
addition thereto and the resulting solution is left to 
stand in a sealed container. 
* * * * a  
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